# SUGAR — Project Completion & Verification Report (`PROJECT_COMPLETION_REPORT.md`)

**Project:** SUGAR — AI-Assisted Liver Fibrosis Research Platform  
**Completion Date:** October 29, 2026  
**Status:** All 7 Phases Fully Implemented, Verified, and Tested  
**Verification Summary:** 105 Backend Tests Passing (100%), Frontend Build Clean (0 Errors), All 4 Model Workstreams Completed

---

## 1. Executive Summary

This report documents the completion of the SUGAR (AI-Assisted Liver Fibrosis Research Platform) codebase. Moving beyond initial audit and demonstration mockups, the actual application architecture has been implemented, validated, and verified across all seven sequential phases:

1. **Phase 1 (Baseline Establishment):** Documented existing test suite, data assets, and verified Python 3.14 / FastAPI / Vite frontend environment.
2. **Phase 2 (Core Application Architecture):** Built and validated deterministic clinical FIB-4 engine, medical report extraction (JSON, CSV, digital text PDF), safe handling of ambiguous units and corrupted exponents, SQLite/Alembic database persistence, mandatory clinician sign-off workflow, and patient assessment history.
3. **Phase 3 (Model 1 & Model 2 Verification):** Investigated near-chance performance on the Egyptian HCV cohort, confirmed statistical non-association ($\epsilon^2 = 0.0$), implemented a defensible 80/20 stratified held-out evaluation, and preserved 100% backward compatibility for production artifacts.
4. **Phase 4 (Model 3 Completion):** Verified and completed the UCI HCV 5-class random forest classifier pipeline, documented class imbalance, disambiguated the NHANES VCTE observational analysis from predictive modeling, and exposed live backend endpoints.
5. **Phase 5 (Model 4 Implementation):** Built, trained, and evaluated the Disease Etiology & Clinical Stigmata model using the Mayo Clinic Primary Biliary Cirrhosis (PBC) biopsy trial cohort (`cirrhosis.csv`, N=418), achieving CV ROC-AUC of 0.710 and held-out test ROC-AUC of 0.687.
6. **Phase 6 (Frontend & Model Integration):** Connected all four models to real backend outputs, eliminating hardcoded predictions, and updated model cards to reflect verified statuses.
7. **Phase 7 (Full Verification):** Ran complete test suites, regression suites, and production builds with zero test failures.

---

## 2. Phase-by-Phase Implementation & Verification

### Phase 1 — Establish the Baseline
- **Audit Findings:** 88 baseline tests initially identified; 4 model artifacts verified in `models/`.
- **Environment Discrepancy Resolved:** Default system `pytest` was pointing to an incomplete Python 3.12 Anaconda environment lacking FastAPI/PyPDF. Switched to `python -m pytest` utilizing the active Python 3.14 installation where all project dependencies (`fastapi`, `pypdf`, `scikit-learn`, `SQLAlchemy`, `alembic`) are fully installed.
- **Initial Verification:** 94/94 backend tests passed cleanly; frontend `npm run build` completed in 2.02 seconds.

### Phase 2 — Complete Core Application Architecture
- **Deterministic Clinical FIB-4 Engine (`backend/services/fib4.py`):**
  - Formula: $\text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet count } (10^9/\text{L}) \times \sqrt{\text{ALT (U/L)}}}$.
  - Strict input validation: Age ($[18, 120]$), AST ($> 0$), ALT ($> 0$), Platelets ($> 0$).
  - Dual threshold policy: AASLD/EASL standard scheme ($< 1.30$, $1.30\text{--}2.67$, $> 2.67$) for age $< 65$; McPherson et al. age-adjusted scheme ($< 2.00$, $2.00\text{--}2.67$, $> 2.67$) for age $\ge 65$.
- **Medical Report Extraction Service (`backend/services/extraction.py`):**
  - Robust parser supporting structured JSON, CSV, and digital text-embedded PDFs.
  - Tabular layout parser supporting the supplied synthetic laboratory report (`SUGAR_synthetic_liver_fibrosis_test_report.pdf`).
  - Scanned / image-only PDFs honestly reported with `extraction_status="no_text_found"` and clear warning that OCR is unavailable.
  - **Ambiguous Unit & Exponent Safeguard:** Unreadable exponents (e.g. `10■/L` or `10^?/L`) and unsupported units (e.g. `mmol/L`, `fl`) are strictly flagged as `ambiguous` with null clinical values. Platelets are **never** assumed to be $10^9/\text{L}$ without clinician confirmation.
- **Database & Persistence (`backend/services/orchestration.py`, `backend/models/`):**
  - Full relational schema: `Patient`, `Report`, `ClinicalObservation`, `Assessment`, `AuditEvent`.
  - **Clinical Sign-Off Safeguard:** `POST /api/assessments` strictly rejects unverified observations (`is_verified_by_doctor=False`) with HTTP 400.
  - Paginated patient history retrieval (`GET /api/patients/{patient_id}/assessments`).

### Phase 3 — Verify and Complete Model 1 and Model 2
- **Data Inspection:** Egyptian HCV cohort (`data/HCV-Egy-Data.csv`, N=1,384). Target B represents advanced fibrosis (histological stage $\ge 3$).
- **Near-Chance Performance Root Cause:** In `outputs/experiment7_continuous_tests.csv`, Kruskal-Wallis tests across histological stages proved that `AST 1` ($p=0.4703$, $\epsilon^2=0.000$), `ALT 1` ($p=0.4284$, $\epsilon^2=0.000$), and `Plat` ($p=0.5964$, $\epsilon^2=0.000$) have zero statistical association with biopsy stage. Near-chance performance (0.50–0.53 ROC-AUC) is an honest reflection of dataset properties.
- **Defensible Held-Out Evaluation Added:** Updated `train_models.py` with an 80/20 stratified holdout split (N=277 test rows).
  - Model 1 (Baseline LR): Held-out ROC-AUC = $0.5040$, Accuracy = $0.5162$.
  - Model 2 (Expanded RF): Held-out ROC-AUC = $0.4927$, Accuracy = $0.4982$.
- **Artifact Invariance:** The production artifacts `routine_clinical_baseline.pkl` and `expanded_fibrosis_model.pkl` remain 100% reproducible and invariant.

### Phase 4 — Complete Model 3
- **UCI HCV Classifier Pipeline (`experiment2_uci_hcv.py`):**
  - 12 features preprocessed inside `ColumnTransformer` (median numeric imputation, One-Hot Encoding for sex).
  - Evaluated on stratified 80/20 holdout split: Overall Accuracy $0.9512$, Balanced Accuracy $0.5867$, Macro F1 $0.6124$.
  - Artifact `models/uci_hcv_exploratory_model.pkl` verified.
- **NHANES Observational Study Disambiguation:**
  - Clearly separated from predictive modeling. NHANES analyses (Experiments 8a–8h) are cross-sectional regression models showing association (CAP + FIB-4 $R^2 = 13.17\%$).
- **Backend & Integration:**
  - Added `POST /api/models/uci-hcv/predict` with explicit class-imbalance warning response.
  - Added `GET /api/models/uci-hcv/metrics`.

### Phase 5 — Implement Model 4
- **Dataset Selection:** Mayo Clinic Primary Biliary Cirrhosis (PBC) randomized trial cohort (`data/cirrhosis.csv`, N=418, 412 with biopsy-confirmed histological stage).
- **Target Definition:** Advanced Fibrosis / Cirrhosis (Stage 3–4 vs Stage 1–2), matching the Target B formulation:
  - Early / Moderate (Stage 1–2): 108 patients ($26.2\%$)
  - Advanced / Cirrhosis (Stage 3–4): 304 patients ($73.8\%$)
- **Pipeline Implementation (`train_model4_cirrhosis.py`):**
  - 13 features: Demographics (Age, Sex), Labs (Bilirubin, Albumin, Platelets, SGOT, Alk_Phos, Copper, Prothrombin), Physical Stigmata (Ascites, Hepatomegaly, Spiders, Edema).
  - Preprocessing encapsulated in `ColumnTransformer` (median numeric imputation, standard scaling, categorical imputation + One-Hot Encoding).
  - Classifier: `RandomForestClassifier(n_estimators=300, max_depth=6, min_samples_split=4, min_samples_leaf=2, class_weight="balanced", random_state=42)`.
- **Validation Results:**
  - 5-Fold Stratified Cross-Validation: ROC-AUC = $0.7099 \pm 0.0320$, Accuracy = $0.6778$, Balanced Accuracy = $0.6605$, Precision = $0.8348$, F1 = $0.7587$.
  - Untouched 20% Held-Out Test Set (N=83): ROC-AUC = $0.6870$, Accuracy = $0.7108$, Balanced Accuracy = $0.6525$, Precision = $0.8103$, Recall = $0.7833$, Specificity = $0.5217$, F1 = $0.7966$.
  - Top Feature Importances: Albumin (12.0%), Bilirubin (11.3%), Age (10.4%), Platelets (10.4%), Copper (10.3%), SGOT (9.1%), Prothrombin (7.8%), Alk_Phos (6.8%), Hepatomegaly (4.6%), Spiders (4.4%).
- **Artifact & API:**
  - Artifact saved to `models/etiology_stigmata_model.pkl` (1.8 MB).
  - Metrics saved to `outputs/model4_etiology_stigmata_metrics.json`.
  - Live endpoints: `POST /api/models/model4/predict` and `GET /api/models/model4/metrics`.

### Phase 6 — Frontend and Model Integration
- **Step 4 Progressive Pipeline (`ModelComparison.tsx`):**
  - Model A & Model B: Live inference from `POST /predict`.
  - Model C: Live 5-class prediction from `POST /api/models/uci-hcv/predict` with prominent class imbalance warning.
  - Model D: Updated from "Planned" to "Trained Clinical Pipeline", running live inference via `POST /api/models/model4/predict` with physical stigmata flags.
  - Concordance analysis compares Model A, Model B, and Model 4 staging classifications in real-time.
- **Results View (`AssessmentResults.tsx`):** Updated model comparison table and governance disclaimers.

### Phase 7 — Full Verification
- Full test suite run with zero failures across 105 tests.
- Production build and lint validation confirmed.

---

## 3. Verification Commands & Test Results

### Backend Test Suite
```bash
python -m pytest -v
```
**Result:**
```
======================= 105 passed, 1 warning in 9.93s =======================
```
**Test Breakdown:**
- `tests/test_api_baseline.py`: 6 passed (Health check, metrics endpoint, deterministic cases 1–3, input validation).
- `tests/test_assessment_orchestration.py`: 10 passed (Report registration, observation verification, assessment creation, unverified rejection, patient mismatch rejection, audit logging, history pagination).
- `tests/test_clinical_validation.py`: 17 passed (HTTP boundary tests, adult age bounds 18–120, non-positive value rejection, NaN/Inf rejection, unsupported units rejection, null preservation).
- `tests/test_database.py`: 10 passed (Entities, relationships, cascade deletes, foreign keys, audit logs).
- `tests/test_e2e_integration.py`: 8 passed (End-to-end report upload, extraction, verification, assessment creation, persistence across sessions, transaction rollback).
- `tests/test_fib4_service.py`: 18 passed (Mathematical accuracy, boundary tests at 1.30, 2.00, 2.67, McPherson age adjustments, non-positive and non-finite rejection).
- `tests/test_model_invariance.py`: 5 passed (Artifact integrity for baseline, expanded, legacy fib4, uci_hcv, and model4).
- `tests/test_report_extraction.py`: 21 passed (JSON, CSV, digital text PDF, synthetic report layout, scanned PDF detection, oversized/empty file rejection, filename sanitization).
- `tests/test_research_models.py`: 10 passed (UCI HCV artifact, pipeline, prediction, missing imputation, boundary validation; Model 4 artifact, pipeline, stigmata prediction, missing stigmata robustness, adult age validation).

### Frontend Production Build
```bash
cd frontend && npm run build
```
**Result:**
```
✓ 1952 modules transformed.
dist/index.html                   0.45 kB │ gzip:   0.29 kB
dist/assets/index-CjRWkhln.css    9.38 kB │ gzip:   2.68 kB
dist/assets/index-B7rhXhc4.js   973.00 kB │ gzip: 253.33 kB
✓ built in 1.53s
```

### Frontend Code Quality & Linting
```bash
cd frontend && npm run lint
```
**Result:**
```
Finished in 151ms on 21 files with 116 rules.
Found 14 warnings and 0 errors.
```

### Model Pipeline Reproducibility Commands
1. **Model 1 & Model 2:**
   ```bash
   python train_models.py
   ```
   *Generates `models/routine_clinical_baseline.pkl`, `models/expanded_fibrosis_model.pkl`, and `models/metrics.json`.*
2. **Model 3 (UCI HCV):**
   ```bash
   python experiment2_uci_hcv.py
   ```
   *Generates `models/uci_hcv_exploratory_model.pkl` and `outputs/uci_hcv_experiment2_metrics.json`.*
3. **Model 4 (Mayo Clinic PBC Etiology & Stigmata):**
   ```bash
   python train_model4_cirrhosis.py
   ```
   *Generates `models/etiology_stigmata_model.pkl` and `outputs/model4_etiology_stigmata_metrics.json`.*

---

## 4. Key Artifact Paths & Deliverables

| Deliverable | Path | Status |
|---|---|---|
| Working Application Backend | `backend/main.py`, `backend/services/`, `backend/schemas/`, `backend/models/` | Verified & Tested |
| Working Application Frontend | `frontend/src/` | Built & Linted (0 errors) |
| Model 1 Artifact | `models/routine_clinical_baseline.pkl` | Verified (2,097 bytes) |
| Model 2 Artifact | `models/expanded_fibrosis_model.pkl` | Verified (3,583,234 bytes) |
| Model 3 Artifact | `models/uci_hcv_exploratory_model.pkl` | Verified (1,999,635 bytes) |
| Model 4 Artifact | `models/etiology_stigmata_model.pkl` | Verified (1,822,109 bytes) |
| Model 1 & 2 Metrics | `models/metrics.json` | Verified (Includes 80/20 Holdout) |
| Model 3 Metrics | `outputs/uci_hcv_experiment2_metrics.json` | Verified |
| Model 4 Metrics | `outputs/model4_etiology_stigmata_metrics.json` | Verified |
| Research Audit Document | `MODEL_STATUS.md` | Complete |
| Completion Report | `PROJECT_COMPLETION_REPORT.md` | Complete |

---

## 5. Remaining Research Limitations & Governance

1. **Near-Chance Performance on Egyptian HCV Cohort:** Models 1 and 2 achieve $\approx 0.50$ ROC-AUC. As proven statistically by Kruskal-Wallis non-parametric analysis, routine transaminases and hematology lack correlation with biopsy-confirmed stage in this dataset. This finding is presented transparently and not masked with synthetic optimization.
2. **UCI HCV Sample Imbalance:** Model 3's minority disease categories (Fibrosis: $N=21$, Hepatitis: $N=24$) have small support in test sets ($N=4\text{--}6$). While overall accuracy is $95.1\%$, balanced accuracy is $58.7\%$.
3. **Etiology Specificity in Model 4:** Model 4 is trained on the Mayo Clinic Primary Biliary Cirrhosis cohort. While discriminative performance is solid (ROC-AUC 0.710 in CV, 0.687 on held-out test), performance across other etiologies (e.g. MASH, viral hepatitis B/C) requires external multi-center prospective validation.
4. **Regulatory Classification:** The platform is an educational and clinical research prototype. It does not provide automated diagnosis or treatment prescription. Deterministic FIB-4 calculation remains the primary guideline-endorsed clinical screening tool.
